AI in Biotech
Artificial intelligence and machine learning across the bio-economy — AI drug discovery, protein design, genomics, and smart bioprocessing.
Latest AI in Biotech news
13 AI drug discovery companies you need to watch in 2025
Read at Labiotech.eu →INmune Bio Inc. and Quantum Computing Inc. partner to apply quantum optimization and AI to advance Alzheimer’s drug research and explore new applications for XPro
Read at News-Medical →Investment Opportunities & Tech Trends in Life Sciences
Read at VC Magazin →BWB Boston: BMS discusses the struggle of bringing data into hybrid models
Read at BioProcess International →Thermo Fisher Expands Drug Development and Manufacturing
Read at Technology Networks →How modern synthetic tools are transforming chemistry and drug discovery
Read at News-Medical →From the knowledge base
ASHG: Long-Read Genomics Meets Clinical Data in PacBio, Verily Health AI Deal
A multi-year collaboration will connect PacBio's HiFi sequencing with Verily Pre, combining long-read genomic and clinical data for biomedical research and AI model development.
5 iced coffees we're bringing to a job interview
A viral post sparked debate around the professionalism of iced coffee. Explore the gallery for our five natural iced coffee picks sure to impress.
It will take more than data to improve traceability in the cotton supply chain
New research supported by Cotton Diaries explores the idea of "relational traceability" and making farmers a key source of intel.
Former MIT professor David Sabatini awarded $6M in defamation case
A Massachusetts jury awarded $6 million in damages to prominent biologist David Sabatini, years after sexual harassment allegations led to his ouster from MIT. Roughly five years ago, Sabatini brought the
How this plastic-free personal care brand tackles men's reproductive health
Learn about Old Salt Grooming's plastic-free product line paired with broader messaging around men's reproductive health and the environmental cost of personal care.
Antheia gets $80M conditional DOD loan to onshore to the US
Biosynthesis manufacturer Antheia has won a conditional loan of $80 million from the US Department of Defense to help boost the domestic production of generic drugs. "Over time, we aim to manufacture Antheia's full pipeline ...